Related Experiment Videos
Increased prostacyclin biosynthesis in patients with osteoid osteoma
G Ciabattoni1, F Tamburrelli, F Greco
1Department of Pharmacology, Catholic University School of Medicine, Rome, Italy.
Eicosanoids
|January 1, 1991
Summary
Osteoid osteoma, a bone tumor, shows significantly elevated prostaglandin E2 (PGE2) and prostacyclin (PGI2) synthesis. This enhanced PGI2 production in vivo is reversible after tumor removal.
Area of Science:
- Biochemistry
- Oncology
- Pharmacology
Background:
- Osteoid osteoma is a benign bone tumor known for pain relieved by NSAIDs.
- Elevated prostaglandin levels are a hallmark of osteoid osteoma lesions.
Purpose of the Study:
- To investigate prostaglandin E2 (PGE2) and prostacyclin (PGI2) synthesis in osteoid osteoma.
- To assess in vivo PGI2 production and its reversibility after surgical treatment.
Main Methods:
- In vitro incubation of osteoid osteoma nidus explants to measure PGE2 and PGI2 synthesis.
- Measurement of urinary 2,3-dinor-6-keto-PGF1 alpha, a PGI2 metabolite, before and after surgery.
- Comparison of prostaglandin levels in patients with control subjects.
Main Results:
- Osteoid osteoma explants showed 32-fold higher PGE2 and 49-fold higher PGI2 synthesis than normal bone.
- Urinary excretion of a key PGI2 metabolite was nearly double in patients compared to controls.
- Post-surgery, urinary PGI2 metabolite levels significantly decreased, indicating reversibility.
Conclusions:
- Patients with osteoid osteoma exhibit enhanced in vivo prostacyclin (PGI2) biosynthesis.
- The tumor demonstrates an increased capacity for prostaglandin synthesis, contributing to the condition.
- Surgical removal of osteoid osteoma effectively reverses the abnormality in arachidonate metabolism.